PFE vs TMO: Which Is the Better Buy?
Side-by-side comparison of Pfizer Inc. and Thermo Fisher Scientific Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-06-20.
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
VS
Thermo Fisher Scientific Inc. · Healthcare
$464.61
+7.2% upside to fair value
Grade A
High Quality
QuantHub Verdict
TMO has more upside to fair value
(+7.2%).
PFE trades at a lower forward P/E
(19.2x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
PFE |
TMO |
| Current Price |
$25.22 |
$464.61 |
| Fair Value Estimate |
$25.92 |
$498.27 |
| Upside to Fair Value |
+2.8%
|
+7.2%
|
| Market Cap |
$143.7B |
$172.7B |
| Forward P/E |
19.2x
|
25.2x
|
| EV / EBITDA |
12.3x
|
19.1x
|
| Price / Sales |
2.3x
|
3.8x
|
| Price / FCF |
15.2x
|
25.6x
|
| Revenue Growth YoY |
+5.4%
|
+6.2%
|
| Gross Margin |
69.3%
|
39.4%
|
| Operating Margin |
23.4%
|
17.8%
|
| Return on Equity |
8.4%
|
13.3%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
6.6%
|
3.91%
|
| Analyst Consensus |
Hold
|
Strong Buy
|
Investment Thesis
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
Thermo Fisher Scientific is a leading healthcare company specializing in life science tools, diagnostics, and contract research and manufacturing services. It operates with a broad, multi-layered moat driven by scale, integration, and a long-tenured management team. The company exhibits solid fundamentals with a 13.3% ROE, 6.2% revenue growth, and 9.6% earnings growth in the most recent quarter. …
Accumulation Zones
| Metric |
PFE |
TMO |
| Zone Low |
$19.44 |
$373.70 |
| Zone High |
$22.03 |
$423.53 |
| In Buy Zone? |
No
|
No
|